Ganesh Umapathy | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/ganesh-umapathy/Ganesh UmapathyHugo Blox Builder (https://hugoblox.com)en-usFri, 21 Jun 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngGanesh Umapathyhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/ganesh-umapathy/The Alk receptor tyrosine kinase regulates Sparkly, a novel activity regulating neuropeptide precursor in the Drosophila central nervous systemhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/sparkly/Fri, 21 Jun 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/sparkly/Comparison of (177)Lu-octreotate and (177)Lu-octreotide for treatment in human neuroblastoma-bearing micehttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/lu_octreotide_comparison/Thu, 30 May 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/lu_octreotide_comparison/ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/Tue, 02 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expressionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/Tue, 21 Feb 2023 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLChttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/Thu, 01 Sep 2022 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastomahttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/entrectinib_alkal2/Sat, 01 Jan 2022 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/entrectinib_alkal2/ATR inhibition enables complete tumour regression in ALK-driven NB mouse modelshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/Wed, 24 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/In vivo Profiling of the Alk Proximitome in the Developing Drosophila Brainhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_proximitome_brain/Fri, 19 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_proximitome_brain/Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signalinghttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_phospho_interactome/Fri, 19 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_phospho_interactome/ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGalpha) in neuroblastoma patient samples with chromosome arm 2p rearrangementshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/Wed, 01 Jan 2020 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/Targeting anaplastic lymphoma kinase in neuroblastomahttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/targeting_alk_review/Wed, 01 May 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/targeting_alk_review/Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/Tue, 01 Jan 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathwayshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Tue, 20 Nov 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/Wed, 01 Aug 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomashttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/trametinib_alk/Tue, 28 Nov 2017 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/trametinib_alk/The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/Thu, 01 Sep 2016 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/pf06463922_alk/FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinasehttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/fam150_alk_ligands/Tue, 29 Sep 2015 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/fam150_alk_ligands/